According to these data, caspase-1 inhibition may represent a novel therapeutic target in clinical conditions associated with obesity and insulin resistance because its deletion would inhibit the genesis of obesity [41]. Here, CASP1 is linked to obesity due to melanocortin 4 receptor deficiency.